PILLSORTED BLOG 10 MINUTES READ

Safe Prescribing for GLP-1 Medications: Your Complete Guide

GP Safe prescribing for GLP-1 patient

GLP-1 medications like Wegovy and Mounjaro have genuinely transformed lives. They’ve helped thousands of people achieve significant weight loss and improve their overall health and wellbeing. But with great power comes great responsibility – both for prescribers and patients.  

As these “wonder medications” have become more popular and widely available, the market has become crowded with providers. Some are excellent, others… less so. With potentially serious health consequences at stake, it’s crucial you know what to look for in a safe, legitimate provider. 

In this post:

  • Red flags – how to spot unsafe or illegal providers
  • What safe prescribing looks like – licensing, regulations, and professional standards
  • Essential patient checks – what assessments should happen before treatment
  • Monitoring and continuation – why ongoing reviews are critical for your safety
  • Side effects and risks – what to watch out for and how to stay safe
  • Follow-up care – support you should expect during and after treatment
  • The PillSorted difference – how we ensure safe, compliant, patient-first prescribing
  • Questions to ask your provider – to protect your health and make informed choices

These are Serious Medications

GLP-1 medications aren’t lifestyle supplements or cosmetic treatments. They’re powerful prescription medicines that can cause real harm if used inappropriately. Yes, they’re incredibly effective, but they deserve respect and proper medical oversight. 

The good news? When prescribed and monitored correctly, they’re remarkably safe and life-changing. The key is ensuring you’re getting them from the right place, in the right way. 

Red Flags: How to Spot Unsafe Providers 

Illegal GLP-1 prescribing method - direct advertising

Before we dive into what good looks like, here are the warning signs that should make you run: 

🚨 They’re advertising directly to you

If you’re seeing ads for specific GLP-1 medications, that’s actually illegal. Prescription-only medicines can’t be advertised to the public – it’s that simple. Legitimate providers don’t need to break the law to find patients. 

🚨 The price seems too good to be true

Genuine medications have genuine costs. If someone’s offering these medications at dramatically lower prices, ask yourself why. Counterfeit versions containing everything from insulin to unknown substances have been found in the UK. 

🚨 No questions asked

Any provider who’ll give you these medications without proper assessment is putting your health at risk. If it feels too easy, it probably is. 

🚨 No ongoing monitoring

These aren’t “set and forget” medications. If a provider isn’t planning regular check-ins and monitoring, they’re not doing their job properly. 

1. Product Licensing & Approved Indications  

MHRA licensing matters: The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines to ensure they’re safe and effective. Your provider should only offer MHRA-approved GLP-1 medications for their specific licensed uses, though they may be used “off-label” in some cases: 

Wegovy and Mounjaro: Licensed for weight management 

Ozempic and Rybelsus: Licensed for type 2 diabetes only

Licensed prescribing criteria: 

Both medications should be used alongside a reduced-calorie diet and increased physical activity.

2. Prescribing Regulations & Professional Standards 

Avoiding fake and unauthorised supply: This is crucial for your safety. Counterfeit medicines claiming to be Saxenda or Ozempic have been found in the UK, including versions containing insulin which can be harmful. You should only source medicines from legitimate routes with proper prescriptions. 

Warning signs of unsafe providers: 

GPhC regulations: The General Pharmaceutical Council regulates pharmacies and online services to protect public safety. Here’s what they require as a minimum for safe GLP-1 prescribing: 

What does the GpHC say about GLP-1 prescribing? 

3. Essential Patient Checks Before Prescribing 

Identity verification and informed consent: Prescribers must verify your identity and ensure you understand the benefits, risks, and alternatives before starting treatment. 

4. Monitoring & Continuation Criteria 

Regular monitoring requirements: 

5. Safety Considerations & Risk Mitigation 

Common Side Effects: Include nausea, vomiting, diarrhoea, constipation; risk of dehydration.  

Serious but rare complications: Pancreatitis, gallbladder disorders, and allergic reactions can occur. You should be educated about warning signs. 

Hypoglycaemia risk: Possible even in non-diabetic patients – you must recognise symptoms and seek prompt help when needed.  

Contraception considerations: Tirzepatide (Mounjaro) may reduce the effectiveness of oral contraceptives. Those taking oral contraceptives should use barrier methods (like condoms) in addition to their pill for four weeks after starting and four weeks after any dose increase. Wegovy doesn’t have this same requirement.

Adverse Event Reporting: Any suspected adverse drug reactions should be reported via the Yellow Card Scheme. 

6. Follow-up & Ongoing Care 

Comprehensive patient assessment: Patients should be assessed when starting a GLP-1 and then have ongoing monitoring that continues even when you reach your maintenance weight. 

Baseline Assessments: Weight and BMI should be monitored at the start and at regular intervals throughout taking the GLP-1. Other useful things to monitor include: blood pressure, waist measurement and some blood tests e.g. HbA1c to check for diabetes, nutritional levels (e.g. vitamins D, B12), iron levels and thyroid function.  

Regular Monitoring Requirements

Why This All Matters: Real-World Consequences 

We’re not trying to scare you – these medications are genuinely transformative when used properly. But we’ve seen the consequences when they’re not: 

The Pillsorted Difference 

At Pillsorted, we’ve built our entire approach around these safety principles: 

Thorough assessments with qualified clinicians 
Independent verification of your eligibility 
GPhC-registered pharmacy dispensing 
Ongoing monitoring throughout your journey 
Side effect support when you need it 
Maintenance programmes for long-term success 
Transparent, compliant practices – no shortcuts, no compromises  

Questions to Ask Any Provider 

Before committing to treatment anywhere, ask these questions: 

  1. “Are you prescribing within the licensed indications?” 
  1. “How will you verify my BMI and monitor my progress?” 
  1. “What ongoing support and monitoring do you provide?” 
  1. “How do you handle side effects and emergencies?” 
  1. “Is your dispensing pharmacy GPhC-registered?” 
  1. “What’s your plan if I need to stop treatment or switch medications?” 
  1. “Do you use advanced digital signatures for electronic prescriptions as required by law?” 
  1. “What clinical risk management standards do you follow for your prescribing software?” 
  1. “How do you ensure cybersecurity and data protection of my health information?” 

If they can’t give clear, confident answers, consider that a red flag. 

Main takeaways

  • GLP-1 medications can be genuinely life-changing, but only when prescribed and monitored safely. In a crowded market full of shortcuts and corner-cutting, your health deserves better than the cheapest or most convenient option. 
  • Look for providers who take safety seriously, follow proper protocols, and put your long-term health above quick profits. The extra time and investment in proper care isn’t bureaucracy – it’s what stands between you and potentially serious complications. 
  • Your weight loss journey is important, but your safety is paramount. Choose your provider accordingly. 

References

PillSorted

Considering GLP-1 treatment? Our experienced clinicians at Pillsorted follow all safety protocols to ensure your treatment is not just effective, but safe from start to finish. Because your health matters more than cutting corners. 

Call us at 033 4050380 or email help@pillsorted.com.